Skip to main content

SOP on Case Report Form (CRF) Data Entry Procedure for Clinical Trials

 Title: Case Report Form (CRF) Data Entry Procedure for Clinical Trials


Introduction and Purpose:

Case Report Forms (CRFs) are essential documents, whether in paper or electronic format, designed to systematically record all protocol-required information and results for each participant in a clinical trial. Accurate and timely data entry into the CRF is critical for ensuring the trial's proper conduct, evaluating safety and efficacy endpoints, and forming the basis for trial-related reports and publications. This Standard Operating Procedure (SOP) establishes standards for the accurate and timely entry of data into CRFs for clinical trials, following International Council on Harmonization (ICH) Good Clinical Practice (GCP) guidelines. These standards should be adhered to, unless the study contract or Clinical Trial Agreement (CTA) specifies more specific requirements.


Definitions and Acronyms:

  • Clinical Research: Encompasses all research involving human participants, excluding secondary studies using existing biological specimens or data collected without identifiers or publicly available data.
  • Clinical Trial: Refers to clinical research studies involving human participants assigned to an intervention designed to evaluate the effect(s) of the intervention on the participant and the effect being evaluated is a health-related biomedical or behavioral outcome.
  • CFR: Code of Federal Regulations
  • CRO: Contract Research Organization
  • CTA: Clinical Trial Agreement
  • GCP: Good Clinical Practice
  • OSP: Office of Sponsored Projects
  • PI: Principal Investigator
  • SOP: Standard Operating Procedure


Procedure:

Case Report Form Data Entry:

  • Delegated research staff, such as study coordinators, are responsible for identifying, collecting, recording, maintaining, and making available all necessary clinical trial data in the CRF.
  • All data entered into the CRF must have available source documentation, except when source data is directly transmitted into the CRF.
  • Data entry begins after the initiation of the study and the enrollment of participants and should be completed prospectively thereafter.
  • Source documentation (clinic notes, procedure reports, test results, source forms, etc.) should be created contemporaneously with the study visit or available within 2–3 business days in the Electronic Health Record system.
  • All available data should be entered into the CRF within 10 business days of the study visit that generated the data.
  • If data availability is delayed, the PI and study personnel should make efforts to acquire and enter it into the CRF as soon as possible.
  • If the study contract or CTA specifies different data entry requirements, those should be followed instead of this SOP.
  • The PI is responsible for ensuring the accuracy, completeness, legibility, and timeliness of data collected in the CRF to ensure it aligns with the protocol.
  • Every field in the CRF should be completed, and blanks should be avoided. If CRFs are in paper format, blue or black ink should be used, and pencil should never be used.

Queries and Corrections:

  • Queries and requests for changes to CRF entries are common, often following sponsor or Contract Research Organization (CRO) monitoring visits or from data management or pharmacovigilance teams.
  • Any change or correction to a CRF should be dated, initialed, and explained if necessary, and it should not obscure the original entry to maintain an audit trail. This applies to both paper and electronic CRFs.
  • Each query should be addressed, corrected, or appropriately responded to within 10 business days of notification or issuance.

Contracts and Clinical Trial Agreements:

  • During the feasibility and contract negotiation phase for new clinical trials, the study coordinator or appropriate team member should inform the Office of Sponsored Projects (OSP) program officer of the 10 business day data entry requirement outlined in this SOP. This is to prevent shorter data entry requirements from being included in the contract or CTA.

Materials Required:

  • Access to the study's paper or electronic CRF database (may require user training and logon credentials)
  • IRB-approved clinical trial protocol
  • Access to the study contract or CTA, or contact information for the responsible OSP program officer
  • Access to the Electronic Health Record and all other study source data

References:

  • 21 CFR Part 312.62: Investigator Recordkeeping and Record Retention
  • 21 CFR Part 312.68 Inspection of investigator's records and reports
  • ICH Guidance for Industry E6(R2): Good Clinical Practice 4.9

Document Approval:

Labels:

Popular posts from this blog

Human Genome Editing: FDA Draft Guidance Summary

Consideration for Developing Gene Editing Product  1. Genome Editing Methods: Genome editing can be achieved through nuclease-dependent or nuclease-independent methods. Nuclease-dependent methods involve introducing site-specific breaks in DNA using technologies like zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), modified-homing endonucleases, and CRISPR-associated (Cas) nucleases. These breaks can lead to modification of the DNA sequence at the cleavage site. Nuclease-independent methods can change DNA sequences without cleaving the DNA and include techniques like base editing and synthetic triplex-forming peptide nucleic acids. The choice of GE technology should consider factors such as the mechanism of action, the ability to target specific DNA sequences, and the potential to optimize components for efficiency, specificity, or stability. 2. Type and Degree of Genomic Modification: Different GE approaches rely on DNA repair pathways such a...
Read more

Stem loop RT-PCR for Detection of siRNA in Animal Tissues

Step Loop RT-PCR for Detection of Small Interfering RNA (siRNA) The recent publications described a novel used the novel method for the detection of siRNAs using a TaqMan®-based approach. This approach utilizes similar strategy that has been used for microRNA detection. The approach is illustrated in below.  In brief, the RT step occurs in the presence of a stem-loop RT primer that is complementary to the last 6–10 bases of the 3′ end of the antisense strand of the target siRNA. The stem-loop primer contains an additional universal sequence at the 5′ end that facilitates a TaqMan-based detection strategy in the subsequent qPCR step. As in the case of microRNA, the forward primer for qPCR is sequence-specific for the target siRNA. For sequence compositions that yield a low predicted melting temperature (Tm), the forward primer is designed as a tailed primer to help increase Tm. Stem Loop PCR for SiRNA Detection Step 1: Preparation of liver and plasma samples for the quanti...
Read more

Human Gene Therapy for Neurodegenerative Diseases: FDA Guidance Summary

  Neurodegenerative diseases are a diverse group of disorders characterized by the progressive degeneration of the central or peripheral nervous system, and they can have various causes and clinical characteristics. This guidance document is a resource for sponsors on different aspects of product development, preclinical testing, and clinical trial design. It acknowledges the unique challenges and considerations associated with developing GT products for such complex and varied diseases. Below are the key summaries from the guidance. CONSIDERATIONS FOR CHEMISTRY, MANUFACTURING AND CONTROLS (CMC) The considerations for Chemistry, Manufacturing, and Controls (CMC) when developing gene therapy (GT) products for the treatment of neurodegenerative diseases are crucial for ensuring the safety and efficacy of these advanced therapies. Here, we will elaborate on the specific CMC considerations outlined in your text: Route of Administration and Product Volume: Neurodegenerative diseases oft...
Read more

FDA Guidance on Studying Multiple Versions of Cellular or Gene Therapy Products in Early-Phase Clinical Trials

 The purpose of this guidance is to offer advice to sponsors interested in conducting early-phase clinical trials for a single disease involving multiple variations of a cellular or gene therapy product. Sponsors aim to gather preliminary safety and efficacy data for these product variations within a single clinical trial. It's important to note that even though multiple product versions are studied together, each version is distinct and typically requires a separate investigational new drug application (IND) submission to the FDA. The primary goal of these early-phase clinical studies is to inform decisions about which product version(s) should be advanced for further development in later-phase trials. As such, these studies are not designed to provide the main evidence of effectiveness needed for a marketing application. They are generally not statistically powered to demonstrate a significant difference in efficacy between the different study arms. In this guidance, the FDA prov...
Read more

ICH Q8 (R2) Pharmaceutical development (CHMP/ICH/167068/04)

 ICH Q8 (R2) is a guideline titled "Pharmaceutical Development" (CHMP/ICH/167068/04). This guideline is part of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) and provides recommendations for the pharmaceutical development of medicinal products. It offers a structured approach to the development of pharmaceutical products to ensure their quality, safety, and efficacy. Here's an elaboration of ICH Q8 (R2): 1. Purpose of ICH Q8 (R2): The primary purpose of ICH Q8 (R2) is to provide a systematic and science-based approach to pharmaceutical development. The guideline aims to facilitate the design and development of high-quality pharmaceutical products that meet the needs of patients and regulatory authorities. 2. Scope: ICH Q8 (R2) applies to the development of all types of pharmaceutical products, including small molecules, biotechnological products, and other complex medicinal products. 3. Pharmaceutical Develop...
Read more